AstraZeneca Confirms Interest In 'Next-Generation Imbruvica' Play
This article was originally published in Scrip
AstraZeneca has published a short statement confirming that it is "exploring potential strategic options" with Acerta Pharma BV. The move is in response to recent speculation that AstraZeneca is pursuing the Dutch blood cancer company and has offered around $5bn.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.